EntreMed starts phase 1 trial of MKC-1 to treat leukemia

By Lisa Kerner

Charlotte, N.C., Sept. 26 - EntreMed, Inc. began a phase 1 study of its clinical-stage drug candidate, MKC-1, in patients with relapsed or refractory leukemia at the University of Texas MD Anderson Cancer Center in Houston.

"This is the first clinical study where MKC-1 will be given to patients with hematological cancers," vice president and chief medical officer of the Rockville, Md., pharmaceutical company Carolyn F. Sidor said in a news release.

MKC-1, a novel, orally active cell cycle inhibitor, is also being evaluated in a phase 2 clinical study in patients with metastatic breast cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.